ADAGIO MEDICAL HOLDINGS INC (ADGM) Fundamental Analysis & Valuation
NASDAQ:ADGM • US00534B1008
Current stock price
1.03 USD
+0.13 (+14.41%)
At close:
1.0148 USD
-0.02 (-1.48%)
After Hours:
This ADGM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ADGM Profitability Analysis
1.1 Basic Checks
- ADGM had negative earnings in the past year.
- ADGM had a negative operating cash flow in the past year.
- In the past 5 years ADGM reported 4 times negative net income.
- ADGM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -57.99%, ADGM is not doing good in the industry: 71.12% of the companies in the same industry are doing better.
- ADGM's Return On Equity of -202.26% is on the low side compared to the rest of the industry. ADGM is outperformed by 77.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.99% | ||
| ROE | -202.26% | ||
| ROIC | N/A |
ROA(3y)-249.67%
ROA(5y)-150.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ADGM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ADGM Health Analysis
2.1 Basic Checks
- ADGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ADGM has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ADGM has been increased compared to 5 years ago.
- ADGM has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -3.98, we must say that ADGM is in the distress zone and has some risk of bankruptcy.
- ADGM has a Altman-Z score of -3.98. This is in the lower half of the industry: ADGM underperforms 69.52% of its industry peers.
- ADGM has a Debt/Equity ratio of 1.70. This is a high value indicating a heavy dependency on external financing.
- With a Debt to Equity ratio value of 1.70, ADGM is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.98 |
ROIC/WACCN/A
WACC4.64%
2.3 Liquidity
- ADGM has a Current Ratio of 2.44. This indicates that ADGM is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.44, ADGM perfoms like the industry average, outperforming 44.38% of the companies in the same industry.
- ADGM has a Quick Ratio of 2.24. This indicates that ADGM is financially healthy and has no problem in meeting its short term obligations.
- ADGM has a Quick ratio (2.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.44 | ||
| Quick Ratio | 2.24 |
3. ADGM Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 65.93% over the past year.
- Looking at the last year, ADGM shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)65.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- Based on estimates for the next years, ADGM will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.88% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.11%
EPS Next 2Y16.84%
EPS Next 3Y9.29%
EPS Next 5Y-15.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ADGM Valuation Analysis
4.1 Price/Earnings Ratio
- ADGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADGM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.84%
EPS Next 3Y9.29%
5. ADGM Dividend Analysis
5.1 Amount
- No dividends for ADGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ADGM Fundamentals: All Metrics, Ratios and Statistics
1.03
+0.13 (+14.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength11.18
Industry Growth59.01
Earnings (Last)03-27 2026-03-27/bmo
Earnings (Next)05-14 2026-05-14
Inst Owners30.93%
Inst Owner Change0.16%
Ins Owners3.31%
Ins Owner Change2.24%
Market Cap22.88M
Revenue(TTM)N/A
Net Income(TTM)-25.08M
Analysts82.86
Price Target3.57 (246.6%)
Short Float %0.44%
Short Ratio0.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.5%
PT rev (3m)-12.5%
EPS NQ rev (1m)-32.5%
EPS NQ rev (3m)-21.46%
EPS NY rev (1m)4.04%
EPS NY rev (3m)4.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.58
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS0.56
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.99% | ||
| ROE | -202.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-249.67%
ROA(5y)-150.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.56% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.44 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | -3.98 |
F-Score2
WACC4.64%
ROIC/WACCN/A
Cap/Depr(3y)73.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.09%
EPS Next Y43.11%
EPS Next 2Y16.84%
EPS Next 3Y9.29%
EPS Next 5Y-15.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.33%
EBIT Next 3Y-0.27%
EBIT Next 5YN/A
FCF growth 1Y37.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.46%
OCF growth 3YN/A
OCF growth 5YN/A
ADAGIO MEDICAL HOLDINGS INC / ADGM Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ADAGIO MEDICAL HOLDINGS INC (ADGM) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ADGM.
Can you provide the valuation status for ADAGIO MEDICAL HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to ADAGIO MEDICAL HOLDINGS INC (ADGM). This can be considered as Overvalued.
How profitable is ADAGIO MEDICAL HOLDINGS INC (ADGM) stock?
ADAGIO MEDICAL HOLDINGS INC (ADGM) has a profitability rating of 0 / 10.
How financially healthy is ADAGIO MEDICAL HOLDINGS INC?
The financial health rating of ADAGIO MEDICAL HOLDINGS INC (ADGM) is 2 / 10.